Cargando…

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?

BACKGROUND/AIMS: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Young Sok, Lee, Min Sung, Min, Chang Wook, Park, Seong Kyu, Kim, Se Hyung, Yun, Jina, Kim, Hyun Jung, Kim, Kyoung Ha, Kim, Chan Kyu, Lee, Kyu-Taek, Won, Jong-Ho, Hong, Dae Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939503/ https://www.ncbi.nlm.nih.gov/pubmed/27017944 http://dx.doi.org/10.3904/kjim.2015.234

Ejemplares similares

Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome
por: Choi, Mihong, et al.
Publicado: (2020)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies
por: Li, Qingshan, et al.
Publicado: (2015)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease
por: Ju, Hee Young, et al.
Publicado: (2016)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin
por: Seo, Jeongmin, et al.
Publicado: (2021)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Favorable outcomes with durable chimerism after hematopoietic cell transplantation using busulfan and fludarabine-based reduced-intensity conditioning for pediatric patients with hemophagocytic lymphohistiocytosis
por: Suh, Jin Kyung, et al.
Publicado: (2022)

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients
por: Lee, Ga Hye, et al.
Publicado: (2022)

Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation
por: Tamaki, Masaharu, et al.
Publicado: (2023)

Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Challenges to be addressed in management of patients with sinusoidal obstruction syndrome after hematopoietic cell transplantation
por: Park, Seong Kyu, et al.
Publicado: (2022)

Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea
por: Ji, Young Sok, et al.
Publicado: (2023)

Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients
por: Sheshadri, Ajay, et al.
Publicado: (2020)

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
por: Butera, Sara, et al.
Publicado: (2021)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation
por: Lee, Jae Geun, et al.
Publicado: (2016)

Anti-thymocyte globulin in haematology: Recent developments
por: Siddiqui, Salahuddin, et al.
Publicado: (2019)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
por: Yoon, Seug Yun, et al.
Publicado: (2018)

Effects of Korean Red Ginseng extract on busulfan-induced dysfunction of the male reproductive system
por: Jung, Seok-Won, et al.
Publicado: (2015)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
por: Tang, Lu, et al.
Publicado: (2023)

NSrp70 is a lymphocyte-essential splicing factor that controls thymocyte development
por: Kim, Chang-Hyun, et al.
Publicado: (2021)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin
por: Suk Lee, Young, et al.
Publicado: (2019)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia
por: Kim, Hyun Jung, et al.
Publicado: (2012)

Safety and Effectiveness of Central Venous Catheterization in Patients with Cancer: Prospective Observational Study
por: Kim, Hyun Jung, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_46r3ej74sn8cno4apou6qqi5tg